SAN DIEGO (AP) _ Halozyme Therapeutics Inc. (HALO) on Tuesday reported a fourth-quarter loss of $27.4 million, after reporting a profit in the same period a year earlier.
On a per-share basis, the San Diego-based company said it had a loss of 21 cents.
The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 30 cents per share.
The biopharmaceutical company posted revenue of $39 million in the period, also exceeding Street forecasts. Three analysts surveyed by Zacks expected $38.3 million.
For the year, the company reported that its loss widened to $103 million, or 81 cents per share. Revenue was reported as $146.7 million.
Halozyme Therapeutics expects full-year revenue in the range of $115 million to $130 million.
Halozyme Therapeutics shares have risen 30 percent since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $12.82, a climb of 58 percent in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on HALO at https://www.zacks.com/ap/HALO
Keywords: Halozyme Therapeutics, Earnings Report